SP1 and gastric cancer: Since the PDL1 promoter region has been found to serve as a binding site for SP1 in gastric cancer and rs10815225 polymorphism is related to the overexpression of PD-L1 (25), we reasoned Mit-A (an SP1 inhibitor) could influence the PD-L1 expression in TME.